Clinical data | |
---|---|
Other names | BTRX-246040 |
Routes of administration | By mouth |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C22H23ClF2N4O2S |
Molar mass | 480.96 g·mol−1 |
3D model ( JSmol) | |
| |
|
BTRX-246040, also known as LY-2940094, is a potent and selective nociceptin receptor antagonist which is under development by BlackThorn Therapeutics and Eli Lilly for the treatment of major depressive disorder (MDD). [1] [2] [3] It has demonstrated proof-of-concept clinical efficacy for depression. [4] As of 2017, it is in phase II clinical trials for the treatment of MDD. [1] [2] [3] It was also under investigation for the treatment of alcoholism, and similarly reached phase II clinical studies for this indication, but development was discontinued. [1]
Clinical data | |
---|---|
Other names | BTRX-246040 |
Routes of administration | By mouth |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C22H23ClF2N4O2S |
Molar mass | 480.96 g·mol−1 |
3D model ( JSmol) | |
| |
|
BTRX-246040, also known as LY-2940094, is a potent and selective nociceptin receptor antagonist which is under development by BlackThorn Therapeutics and Eli Lilly for the treatment of major depressive disorder (MDD). [1] [2] [3] It has demonstrated proof-of-concept clinical efficacy for depression. [4] As of 2017, it is in phase II clinical trials for the treatment of MDD. [1] [2] [3] It was also under investigation for the treatment of alcoholism, and similarly reached phase II clinical studies for this indication, but development was discontinued. [1]